| Pancreatic Exocrine Neoplasm altered in cohorts of …ALTERED_INderived109 of 109show fewer |
|---|
| ← altered in cohorts of | CFAP53 114 / 185 cases (62 %) · ssm · TCGA-PAAD | — | — | Pancreatic Adenocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | CXXC1 114 / 185 cases (62 %) · ssm · TCGA-PAAD | — | — | Pancreatic Adenocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | MAPK4 114 / 185 cases (62 %) · ssm · TCGA-PAAD | — | — | Pancreatic Adenocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | MBD1 114 / 185 cases (62 %) · ssm · TCGA-PAAD | — | — | Pancreatic Adenocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | ME2 114 / 185 cases (62 %) · ssm · TCGA-PAAD | — | — | Pancreatic Adenocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | SKA1 114 / 185 cases (62 %) · ssm · TCGA-PAAD | — | — | Pancreatic Adenocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | C18orf54 113 / 185 cases (61 %) · ssm · TCGA-PAAD | — | — | Pancreatic Adenocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | DCC 113 / 185 cases (61 %) · ssm · TCGA-PAAD | — | — | Pancreatic Adenocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | MBD2 113 / 185 cases (61 %) · ssm · TCGA-PAAD | — | — | Pancreatic Adenocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | MEX3C 113 / 185 cases (61 %) · ssm · TCGA-PAAD | — | — | Pancreatic Adenocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | MRO 113 / 185 cases (61 %) · ssm · TCGA-PAAD | — | — | Pancreatic Adenocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | MYO5B 113 / 185 cases (61 %) · ssm · TCGA-PAAD | — | — | Pancreatic Adenocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | POLI 113 / 185 cases (61 %) · ssm · TCGA-PAAD | — | — | Pancreatic Adenocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | STARD6 113 / 185 cases (61 %) · ssm · TCGA-PAAD | — | — | Pancreatic Adenocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | TCF4 113 / 185 cases (61 %) · ssm · TCGA-PAAD | — | — | Pancreatic Adenocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | ALPK2 112 / 185 cases (61 %) · ssm · TCGA-PAAD | — | — | Pancreatic Adenocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | CCDC68 112 / 185 cases (61 %) · ssm · TCGA-PAAD | — | — | Pancreatic Adenocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | DYM 112 / 185 cases (61 %) · ssm · TCGA-PAAD | — | — | Pancreatic Adenocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | DYNAP 112 / 185 cases (61 %) · ssm · TCGA-PAAD | — | — | Pancreatic Adenocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | ELAC1 112 / 185 cases (61 %) · ssm · TCGA-PAAD | — | — | Pancreatic Adenocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | LIPG 112 / 185 cases (61 %) · ssm · TCGA-PAAD | — | — | Pancreatic Adenocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | RAB27B 112 / 185 cases (61 %) · ssm · TCGA-PAAD | — | — | Pancreatic Adenocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | SERPINB10 112 / 185 cases (61 %) · ssm · TCGA-PAAD | — | — | Pancreatic Adenocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | SERPINB7 112 / 185 cases (61 %) · ssm · TCGA-PAAD | — | — | Pancreatic Adenocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | SMAD7 112 / 185 cases (61 %) · ssm · TCGA-PAAD | — | — | Pancreatic Adenocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | ACAA2 111 / 185 cases (60 %) · ssm · TCGA-PAAD | — | — | Pancreatic Adenocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | ATP5F1A 111 / 185 cases (60 %) · ssm · TCGA-PAAD | — | — | Pancreatic Adenocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | ATP8B1 111 / 185 cases (60 %) · ssm · TCGA-PAAD | — | — | Pancreatic Adenocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | C18orf25 111 / 185 cases (60 %) · ssm · TCGA-PAAD | — | — | Pancreatic Adenocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | C18orf32 111 / 185 cases (60 %) · ssm · TCGA-PAAD | — | — | Pancreatic Adenocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | CD226 111 / 185 cases (60 %) · ssm · TCGA-PAAD | — | — | Pancreatic Adenocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | CDH19 111 / 185 cases (60 %) · ssm · TCGA-PAAD | — | — | Pancreatic Adenocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | CDH20 111 / 185 cases (60 %) · ssm · TCGA-PAAD | — | — | Pancreatic Adenocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | CDH7 111 / 185 cases (60 %) · ssm · TCGA-PAAD | — | — | Pancreatic Adenocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | CPLX4 111 / 185 cases (60 %) · ssm · TCGA-PAAD | — | — | Pancreatic Adenocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | CTIF 111 / 185 cases (60 %) · ssm · TCGA-PAAD | — | — | Pancreatic Adenocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | DOK6 111 / 185 cases (60 %) · ssm · TCGA-PAAD | — | — | Pancreatic Adenocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | DSEL 111 / 185 cases (60 %) · ssm · TCGA-PAAD | — | — | Pancreatic Adenocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | ELOA2 111 / 185 cases (60 %) · ssm · TCGA-PAAD | — | — | Pancreatic Adenocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | EPG5 111 / 185 cases (60 %) · ssm · TCGA-PAAD | — | — | Pancreatic Adenocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | KDSR 111 / 185 cases (60 %) · ssm · TCGA-PAAD | — | — | Pancreatic Adenocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | MALT1 111 / 185 cases (60 %) · ssm · TCGA-PAAD | — | — | Pancreatic Adenocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | NEDD4L 111 / 185 cases (60 %) · ssm · TCGA-PAAD | — | — | Pancreatic Adenocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | ONECUT2 111 / 185 cases (60 %) · ssm · TCGA-PAAD | — | — | Pancreatic Adenocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | RELCH 111 / 185 cases (60 %) · ssm · TCGA-PAAD | — | — | Pancreatic Adenocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | RNF152 111 / 185 cases (60 %) · ssm · TCGA-PAAD | — | — | Pancreatic Adenocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | RPL17 111 / 185 cases (60 %) · ssm · TCGA-PAAD | — | — | Pancreatic Adenocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | RPL17-C18orf32 111 / 185 cases (60 %) · ssm · TCGA-PAAD | — | — | Pancreatic Adenocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | SERPINB11 111 / 185 cases (60 %) · ssm · TCGA-PAAD | — | — | Pancreatic Adenocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | SERPINB12 111 / 185 cases (60 %) · ssm · TCGA-PAAD | — | — | Pancreatic Adenocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | SERPINB13 111 / 185 cases (60 %) · ssm · TCGA-PAAD | — | — | Pancreatic Adenocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | SERPINB4 111 / 185 cases (60 %) · ssm · TCGA-PAAD | — | — | Pancreatic Adenocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | SERPINB8 111 / 185 cases (60 %) · ssm · TCGA-PAAD | — | — | Pancreatic Adenocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | TMX3 111 / 185 cases (60 %) · ssm · TCGA-PAAD | — | — | Pancreatic Adenocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | TNFRSF11A 111 / 185 cases (60 %) · ssm · TCGA-PAAD | — | — | Pancreatic Adenocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | TXNL1 111 / 185 cases (60 %) · ssm · TCGA-PAAD | — | — | Pancreatic Adenocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | VPS4B 111 / 185 cases (60 %) · ssm · TCGA-PAAD | — | — | Pancreatic Adenocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | WDR7 111 / 185 cases (60 %) · ssm · TCGA-PAAD | — | — | Pancreatic Adenocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | ZNF532 111 / 185 cases (60 %) · ssm · TCGA-PAAD | — | — | Pancreatic Adenocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | BCL2 110 / 185 cases (59 %) · ssm · TCGA-PAAD | — | — | Pancreatic Adenocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | BOD1L2 110 / 185 cases (59 %) · ssm · TCGA-PAAD | — | — | Pancreatic Adenocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | CCBE1 110 / 185 cases (59 %) · ssm · TCGA-PAAD | — | — | Pancreatic Adenocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | CCDC102B 110 / 185 cases (59 %) · ssm · TCGA-PAAD | — | — | Pancreatic Adenocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | CDKN2B 110 / 185 cases (59 %) · ssm · TCGA-PAAD | — | — | Pancreatic Adenocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | FECH 110 / 185 cases (59 %) · ssm · TCGA-PAAD | — | — | Pancreatic Adenocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | GALR1 110 / 185 cases (59 %) · ssm · TCGA-PAAD | — | — | Pancreatic Adenocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | GRP 110 / 185 cases (59 %) · ssm · TCGA-PAAD | — | — | Pancreatic Adenocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | HAUS1 110 / 185 cases (59 %) · ssm · TCGA-PAAD | — | — | Pancreatic Adenocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | HDHD2 110 / 185 cases (59 %) · ssm · TCGA-PAAD | — | — | Pancreatic Adenocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | HMSD 110 / 185 cases (59 %) · ssm · TCGA-PAAD | — | — | Pancreatic Adenocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | IER3IP1 110 / 185 cases (59 %) · ssm · TCGA-PAAD | — | — | Pancreatic Adenocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | MC4R 110 / 185 cases (59 %) · ssm · TCGA-PAAD | — | — | Pancreatic Adenocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | NARS1 110 / 185 cases (59 %) · ssm · TCGA-PAAD | — | — | Pancreatic Adenocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | PHLPP1 110 / 185 cases (59 %) · ssm · TCGA-PAAD | — | — | Pancreatic Adenocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | PIAS2 110 / 185 cases (59 %) · ssm · TCGA-PAAD | — | — | Pancreatic Adenocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | PIGN 110 / 185 cases (59 %) · ssm · TCGA-PAAD | — | — | Pancreatic Adenocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | PIK3C3 110 / 185 cases (59 %) · ssm · TCGA-PAAD | — | — | Pancreatic Adenocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | PSTPIP2 110 / 185 cases (59 %) · ssm · TCGA-PAAD | — | — | Pancreatic Adenocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | RAX 110 / 185 cases (59 %) · ssm · TCGA-PAAD | — | — | Pancreatic Adenocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | RTTN 110 / 185 cases (59 %) · ssm · TCGA-PAAD | — | — | Pancreatic Adenocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | SEC11C 110 / 185 cases (59 %) · ssm · TCGA-PAAD | — | — | Pancreatic Adenocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | SERPINB2 110 / 185 cases (59 %) · ssm · TCGA-PAAD | — | — | Pancreatic Adenocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | SERPINB3 110 / 185 cases (59 %) · ssm · TCGA-PAAD | — | — | Pancreatic Adenocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | SERPINB5 110 / 185 cases (59 %) · ssm · TCGA-PAAD | — | — | Pancreatic Adenocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | SETBP1 110 / 185 cases (59 %) · ssm · TCGA-PAAD | — | — | Pancreatic Adenocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | SKOR2 110 / 185 cases (59 %) · ssm · TCGA-PAAD | — | — | Pancreatic Adenocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | SLC14A2 110 / 185 cases (59 %) · ssm · TCGA-PAAD | — | — | Pancreatic Adenocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | SMAD2 110 / 185 cases (59 %) · ssm · TCGA-PAAD | — | — | Pancreatic Adenocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | ST8SIA3 110 / 185 cases (59 %) · ssm · TCGA-PAAD | — | — | Pancreatic Adenocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | ST8SIA5 110 / 185 cases (59 %) · ssm · TCGA-PAAD | — | — | Pancreatic Adenocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | ZBTB7C 110 / 185 cases (59 %) · ssm · TCGA-PAAD | — | — | Pancreatic Adenocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | ZCCHC2 110 / 185 cases (59 %) · ssm · TCGA-PAAD | — | — | Pancreatic Adenocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | ELOA3C 109 / 185 cases (59 %) · ssm · TCGA-PAAD | — | — | Pancreatic Adenocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | KRAS 168 / 412 cases (41 %) · ssm · pancreas_ctdna_msk_2025 · largest of 10 cohorts | — | — | Pancreatic Adenocarcinoma | 10 | Observed | cbioportal | graph → |
| ← altered in cohorts of | TP53 149 / 412 cases (36 %) · ssm · pancreas_ctdna_msk_2025 · largest of 10 cohorts | — | — | Pancreatic Adenocarcinoma | 10 | Observed | cbioportal | graph → |
| ← altered in cohorts of | NBPF14 30 / 93 cases (32 %) · ssm · paad_iatlas_prince_2022 | — | — | Pancreatic Adenocarcinoma | 1 | Observed | cbioportal | graph → |
| ← altered in cohorts of | MUC17 21 / 93 cases (23 %) · ssm · paad_iatlas_prince_2022 | — | — | Pancreatic Adenocarcinoma | 1 | Observed | cbioportal | graph → |
| ← altered in cohorts of | ZNF814 20 / 109 cases (18 %) · ssm · paad_utsw_2015 | — | — | Pancreatic Adenocarcinoma | 1 | Observed | cbioportal | graph → |
| ← altered in cohorts of | TTN 56 / 383 cases (15 %) · ssm · paad_qcmg_uq_2016 · largest of 5 cohorts | — | — | Pancreatic Adenocarcinoma | 5 | Observed | cbioportal | graph → |
| ← altered in cohorts of | CDKN2A 37 / 412 cases (9.0 %) · ssm · pancreas_ctdna_msk_2025 · largest of 8 cohorts | — | — | Pancreatic Adenocarcinoma | 8 | Observed | cbioportal | graph → |
| ← altered in cohorts of | SMAD4 34 / 412 cases (8.3 %) · ssm · pancreas_ctdna_msk_2025 · largest of 8 cohorts | — | — | Pancreatic Adenocarcinoma | 8 | Observed | cbioportal | graph → |
| ← altered in cohorts of | SYNE1 27 / 383 cases (7.0 %) · ssm · paad_qcmg_uq_2016 | — | — | Pancreatic Adenocarcinoma | 1 | Observed | cbioportal | graph → |
| ← altered in cohorts of | ARID1A 24 / 412 cases (5.8 %) · ssm · pancreas_ctdna_msk_2025 · largest of 2 cohorts | — | — | Pancreatic Adenocarcinoma | 2 | Observed | cbioportal | graph → |
| ← altered in cohorts of | LRP1B 22 / 383 cases (5.7 %) · ssm · paad_qcmg_uq_2016 | — | — | Pancreatic Adenocarcinoma | 1 | Observed | cbioportal | graph → |
| ← altered in cohorts of | ATM 23 / 412 cases (5.6 %) · ssm · pancreas_ctdna_msk_2025 | — | — | Pancreatic Adenocarcinoma | 1 | Observed | cbioportal | graph → |
| ← altered in cohorts of | KMT2C 21 / 383 cases (5.5 %) · ssm · paad_qcmg_uq_2016 | — | — | Pancreatic Adenocarcinoma | 1 | Observed | cbioportal | graph → |
| ← altered in cohorts of | RNF43 21 / 383 cases (5.5 %) · ssm · paad_qcmg_uq_2016 | — | — | Pancreatic Adenocarcinoma | 1 | Observed | cbioportal | graph → |
| ← altered in cohorts of | RYR1 21 / 383 cases (5.5 %) · ssm · paad_qcmg_uq_2016 | — | — | Pancreatic Adenocarcinoma | 1 | Observed | cbioportal | graph → |
| ← altered in cohorts of | MUC16 20 / 383 cases (5.2 %) · ssm · paad_qcmg_uq_2016 | — | — | Pancreatic Adenocarcinoma | 1 | Observed | cbioportal | graph → |